Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Impairment expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zomedica

Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. It offers products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Its TRUFORMA biosensor platform is designed to assist practitioners in the diagnosis of complex conditions. The company was founded by Gerald L. Solensky. on January 7, 2013 and is headquartered in Ann Arbor, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zomedica reports revenue growth and product advancements amidst profitability challenges

Zomedica's 2022 performance reflects revenue growth and product advancements, though challenges in profitability persist. The company's strategic focus on companion animal healthcare presents growth opportunities through innovation and market stability. Addressing expense management, stock stability, and leveraging market trends will be key for Zomedica's future success.

Zomedica reports robust Q1 earnings, eyes global equine market

Zomedica's Q1 2023 showcased strong revenue growth, particularly driven by TRUFORMA and international sales.
The company's focus on maintaining margins, expanding marketing efforts, and targeting global equine markets positions it for future success.
Challenges include the closure of the cancer assay program and operational hurdles in achieving the 70% gross margin target.
Opportunities lie in the launch of new assays, international expansion, and investor engagement beyond quarterly updates.

Zomedica reports robust Q2 earnings, eyes international expansion and product launches

Zomedica's Q2 performance reflects strong revenue growth and strategic investments for future profitability.
Despite challenges like increased OpEx and lower margins, the company is focused on long-term growth through product launches and market expansion.
Opportunities lie in international market exploration, upcoming product launches, and investor engagement strategies.

Zomedica reports record revenues, eyes global expansion amidst stock challenges

Zomedica's Q3 performance reflects strong revenue growth and strategic acquisitions, despite facing challenges like potential delisting and net losses.
The company's focus on new product launches, international expansion, and partnerships presents opportunities for future growth and market diversification.
Overall, Zomedica aims to drive towards cash flow breakeven by leveraging innovative products and maintaining a strong liquidity position.

Zomedica reports record revenues, eyes profitability through strategic growth

Zomedica's strong financial performance in Q4 2023 and full-year results, coupled with a robust cash position and strategic growth initiatives, position the company for future success.
While facing challenges related to compliance requirements and integration costs, Zomedica's focus on innovation, market expansion, and profitability goals present opportunities for sustained growth.
By balancing operational efficiency, product development, and financial discipline, Zomedica aims to drive revenue growth, enhance market presence, and deliver long-term value to shareholders.

Zomedica reports revenue growth and strong cash position in Q1

Zomedica's Q1 2024 performance showed revenue growth driven by key segments, strong cash position, and focus on operational efficiency. The company faces challenges in managing expenses and achieving aggressive revenue targets. Opportunities lie in expanding product lines, international sales, and maintaining financial strength.

Zomedica reports Q2 revenue growth amidst challenges and opportunities

Zomedica's Q2 performance showed revenue growth but with challenges in sales force and noncash charges.
Strengths include achieving milestones and expanding facilities, while opportunities lie in international expansion.
The company faces the task of managing cash burn and finding a new CFO.
Expectations for the second half of 2024 include revenue growth and operational focus.

Zomedica reports record Q3 revenue, eyes global expansion opportunities

Zomedica's Q3 2024 performance showcased revenue growth, margin strength, and cost reduction efforts, positioning the company for future profitability. Strategic international partnerships and product innovations underscore growth potential.
While challenges in achieving profitability persist, Zomedica's focus on operational efficiency and global expansion presents opportunities for sustained growth. Addressing investor inquiries and executing on strategic initiatives will be key to unlocking future value.
With a solid cash position, ongoing product enhancements, and expansion into new markets, Zomedica is poised for growth. Clear communication on financial targets, operational milestones, and strategic direction will be crucial for investor confidence and market success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The bull market has certainly made new investors look like geniuses, as usual. But now is the true test and ZOM stock isn't likely to pass.

Zomedica Stock Will Burn You as High-Growth Stocks Start to Flag

The share price of the Ann Arbor, Michigan-based animal health company has now gone from a pullback and into a steep decline. Since March 15th, ZOM stock has fallen 68% and is now below the $1 threshold at just $0.79 per share.

Zomedica Stock Is Clearly Going to Keep Moving in the Wrong Direction

ZOM stock attracts plenty of attention for its underlying pet care business and its wild potential but this game may be over. The post Zomedica Is Now a Low-Probability Gamble appeared first on InvestorPlace.

Zomedica Is Now a Low-Probability Gamble

The stock price of Zomedica Corp (NYSEAMERICAN: ZOM) decreased by over 6% during intraday trading. This is why it happened.

Zomedica (ZOM) Stock: Over 6% Decrease Explanation

ANN ARBOR, Mich, May 12, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today reported consolidated financial results for the three months ended March 31, 2021. Amounts, unless specified otherwise, are expressed in U.S. dollars and presented under accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Zomedica Announces First Quarter 2021 Financial Results

Zomedica has potential in a niche business. But the price of ZOM stock does not yet reflect that.

Zomedica Stock Is Another Hyped-Up Reddit Play That Can't Escape Reality

If Truforma truly is a game-changer, there's hope the company could grab part of a potential $10.5 billion animal diagnostics market. The post Why Zomedica Stock Isn't Worth Buying Right Now appeared first on InvestorPlace.

Why Zomedica Stock Isn't Worth Buying Right Now

Cinedigm

Castor Maritime Inc

Farmmi

Best reopening penny stocks for your 2021 watchlist The post 4 Reopening Penny Stocks For Your 2021 Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Reopening Penny Stocks For Your 2021 Watchlist

SNDL Inc.

Block

Stocks are always doing one of three things: Moving higher, moving lower or staying the same. When they're moving higher the bulls (buyers) control the market.

3 Reddit Stocks In Meltdown Mode: Is A Rally On The Horizon?

While ZOM stock has been highly volatile, the business is progressing. The Truforma platform has launched and we'll start seeing revenue figures soon.

Zomedica: After a Wild Winter, It's Back to Business

The stock price of Zomedica Corp (NYSEAMERICAN: ZOM) fell from $0.96 to $0.90 today. This is why it happened.

ZOM Stock: From $0.96 To $0.90 (6.27% Decrease) Explanation

Cenntro Electric Group

Ocugen, Inc.

Traders appear to be rotating out of these former highfliers.

Why Zomedica, Naked Brand, Ocugen, and Other Reddit Stocks Crashed Today

The music appears to be slowing for retail favorite ZOM stock, so the question is, will the volume get turned up, or will the music stop? The post As Zomedica Stock Loses Altitude, Is It Cheap Enough for a Buy Today?

As Zomedica Stock Loses Altitude, Is It Cheap Enough for a Buy Today?

Zomedica may be worth a gamble at some point, but for now you can expect ZOM stock to continue falling well below $1 per share. The post Investor Impatience Will Send Zomedica Stock Back Below a Dollar appeared first on InvestorPlace.

Investor Impatience Will Send Zomedica Stock Back Below a Dollar

C3.ai

Cronos Group

Enphase Energy

Li Auto Inc.

MP Materials

Palo Alto Networks

Splunk

Tuscan Holdings

Are you looking for the top stocks of 2021? InvestorPlace pros are betting on these 11 bullseye investments in red-hot themes.

Top Stocks 2021: 11 Bullseye Stock Picks for Your Must-Buy List

ZOM stock makes as much sense as it ever has right now. Truforma's best days are in front of it which is also true of Zomedica shares.

Why Zomedica Is a Great Speculative Play Right Now

Koss

Luminar Technologies

Senseonics Holdings

Electrameccanica

ZK International Group

While cheap stocks have captured the imagination of speculators everywhere, you should avoid this space until it stabilizes. The post 7 Cheap Stocks to Avoid Until the Hype Retreats appeared first on InvestorPlace.

7 Cheap Stocks to Avoid Until the Hype Retreats

ZOM stock has pulled back sharply from its peak price, but Zomedica has an opportunity as it seeks to expand its market presence. The post Sales Model Shift Should Provide a Long-Term Boost for Zomedica appeared first on InvestorPlace.

Sales Model Shift Should Provide a Long-Term Boost for Zomedica

ZOM stock is very attractive today, currently well below its target value of $1.63 and assuming it takes 10% of the pet diagnostic market. The post Zomedica Stock Is Very Attractive Here As Its New Product Launch Takes Off appeared first on InvestorPlace.

Zomedica Stock Is Very Attractive Here As Its New Product Launch Takes Off

ZOM stock double peaked last month before falling sharply, as investors await for Truforma's launch to pay off handsomely. The post Why Zomedica Stock is a Pure Gamble Right Now appeared first on InvestorPlace.

Why Zomedica Stock is a Pure Gamble Right Now

The stock price of Zomedica Corp (NYSEAMERICAN: ZOM) increased by 19.79% yesterday. This is why it happened.

ZOM Stock: 19.79% Increase Explanation

Bionano Genomics

Why Ocugen, Zomedica, Naked Brand, and Other Reddit Stocks Soared Today

Asensus Surgical

GT Biopharma Inc

These biotech penny stocks have begun turning heads in April 2021 The post 3 Penny Stocks To Watch As Biotech Surges In April 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks To Watch As Biotech Surges In April 2021

GameStop

Two months ago, the Reddit traders and day trading community thought investing was easy. Everything was going up, but things sure have changed.

3 Popular Reddit Stocks That Are Melting Down

Penny stocks are all the rage. Everyone's looking for the next GameStop.

News for Zomedica Stock (ZOM)